Robert Szewc, MD
Nephrology · San Antonio, TXNPI 1992759476
Payments from drug & device makers
Across 1,177 payments — averaging $1255.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$801K
- GSK$283K
- AstraZeneca$216K
- CSL Behring$152K
- Eli Lilly$19K
- Medtronic$2K
- plus $5K from 29 others
What the payments were for
- Travel & lodging$3,68333%
- Food & beverage$7,58567%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 801 | $800,754 |
| GSK | 38 | $283,116 |
| AstraZeneca(2 entities) | 55 | $215,744 |
| CSL Behring | 49 | $151,964 |
| Eli Lilly | 12 | $18,517 |
| Medtronic(2 entities) | 14 | $2,031 |
| Amgen(2 entities) | 50 | $1,008 |
| Bayer | 19 | $416 |
| Aurinia Pharma U.S., Inc. | 11 | $396 |
| Outset Medical Inc | 5 | $355 |
| Mallinckrodt Hospital Products Inc. | 15 | $352 |
| OPKO Pharmaceuticals, LLC | 28 | $340 |
| Novo Nordisk | 15 | $337 |
| Otsuka America Pharmaceutical, Inc. | 12 | $254 |
| Philips North America LLC | 2 | $214 |
| Angiodynamics, Inc. | 2 | $212 |
| Lilly USA, LLC | 10 | $198 |
| Travere Therapeutics, Inc. | 12 | $188 |
| Cardiva Medical, Inc. | 1 | $127 |
| Calliditas Therapeutics US Inc. | 4 | $108 |
| ANI Pharmaceuticals, Inc. | 5 | $106 |
| Pfizer | 1 | $93 |
| Gastroklenz, Inc. DBA Cloudcath | 1 | $76 |
| Ardelyx, Inc. | 3 | $46 |
| Cormedix Inc. | 1 | $36 |
| Baxter Healthcare | 1 | $30 |
| Novartis | 2 | $30 |
| Boehringer Ingelheim | 1 | $28 |
| Abbott | 1 | $24 |
| Quanta Dialysis Technologies Inc | 1 | $22 |
| Fresenius USA Marketing, Inc. | 1 | $19 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Bard Peripheral Vascular, Inc. | 1 | $17 |
| Vantive US Healthcare LLC | 1 | $16 |
| Amicus Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELLIPSYS VASCULAR ACCESS SYSTEM$1,529
- SYMPLICITY G3$271
- FARXIGA$234
- Auryon Laser System 100-120 Vac$200
- LUPKYNIS$130
- Cardiva VASCADE 6/7F VCS$127
- EVENITY$122
- IGT Devices Und$114
How this compares
$1,477,205 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 12 | $216,704 |
| MounjaroTirzepatide | 133 | $159,482 |
| VelphoroSucroferric Oxyhydroxide | 27 | $115,429 |
| OzempicSemaglutide | 80 | $99,184 |
| FarxigaDapagliflozin Propanediol | 100 | $90,743 |
| RayaldeeCalcifediol | 48 | $64,187 |
| LokelmaSodium Zirconium Cyclosilicate | 65 | $52,256 |
| KerendiaFinerenone | 37 | $45,263 |
| Sevelamer Carbonate | 93 | $31,505 |
| JanuviaSitagliptin Phosphate | 25 | $29,009 |
| Cinacalcet Hcl | 33 | $26,547 |
| JardianceEmpagliflozin | 21 | $23,826 |
| TrulicityDulaglutide | 19 | $18,206 |
| EliquisApixaban | 17 | $17,970 |
| EntrestoSacubitril/Valsartan | 20 | $16,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $254 | $216,70412 claims |
| Lilly USA, LLCMounjaro, Trulicity | $198 | $177,688152 claims |
| AstraZenecaFarxiga, Lokelma | $215,744 | $142,999165 claims |
| Fresenius USA Marketing, Inc.Velphoro | $19 | $115,42927 claims |
| Novo NordiskOzempic | $337 | $99,18480 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $340 | $64,18748 claims |
| BayerKerendia | $416 | $45,26337 claims |
| Boehringer IngelheimJardiance | $28 | $23,82621 claims |
| PfizerEliquis | $93 | $17,97017 claims |
| NovartisEntresto | $30 | $16,18620 claims |
| Akebia Therapeutics IncAuryxia | $800,754 | $8,32512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,070 nephrology providers in Texas.
Other nephrology in San Antonio
- Pablo PergolaSan Antonio$14.2M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Wesley CalhounSan Antonio$3.5M
- Shweta BansalSan Antonio$1.7M
- Rashid SharafSan Antonio$661K
- Varshasb BroumandSan Antonio$538K
- Luis VelezSan Antonio$505K
- Steven GougeSan Antonio$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.